Global Natural Killer (NK) Cell Therapeutics Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Natural Killer (NK) Cell Therapeutics Market Insights, Forecast to 2034
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
Market Analysis and InsightsGlobal Natural Killer (NK) Cell Therapeutics Market
Global Natural Killer (NK) Cell Therapeutics market is expected to reach to US$ 265.8 million in 2024, with a positive growth of %, compared with US$ 255.8 million in 2022. Backed with the increasing demand from downstream industries, Natural Killer (NK) Cell Therapeutics industry is evaluated to reach US$ 324.8 million in 2029. The CAGR will be 3.4% during 2024 to 2029.
The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.
Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.
Report Covers
This report presents an overview of global Natural Killer (NK) Cell Therapeutics market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Natural Killer (NK) Cell Therapeutics market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Chipscreen Biosciences
Affimed NV
Altor BioScience
Innate Pharma
Takeda
Sorrento Therapeutics
NantKwest
Bristol-Myers Squibb
NKT
Henry Ford Health Services
Segment by Type
Mogamulizumab
Lorvotuzumab Mertansine
Others
Cancer
Cardiovascular Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Natural Killer (NK) Cell Therapeutics introduction, etc. Natural Killer (NK) Cell Therapeutics Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Natural Killer (NK) Cell Therapeutics
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Natural Killer (NK) Cell Therapeutics Market
Global Natural Killer (NK) Cell Therapeutics market is expected to reach to US$ 265.8 million in 2024, with a positive growth of %, compared with US$ 255.8 million in 2022. Backed with the increasing demand from downstream industries, Natural Killer (NK) Cell Therapeutics industry is evaluated to reach US$ 324.8 million in 2029. The CAGR will be 3.4% during 2024 to 2029.
The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.
Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.
Report Covers
This report presents an overview of global Natural Killer (NK) Cell Therapeutics market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Natural Killer (NK) Cell Therapeutics market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Chipscreen Biosciences
Affimed NV
Altor BioScience
Innate Pharma
Takeda
Sorrento Therapeutics
NantKwest
Bristol-Myers Squibb
NKT
Henry Ford Health Services
Segment by Type
Mogamulizumab
Lorvotuzumab Mertansine
Others
Segment by Application
Cancer
Cardiovascular Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Natural Killer (NK) Cell Therapeutics introduction, etc. Natural Killer (NK) Cell Therapeutics Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Natural Killer (NK) Cell Therapeutics
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices